Drug Profile
Quazolast
Alternative Names: REV 3988; RG 3988; RHC 3988Latest Information Update: 11 Aug 1997
Price :
$50
*
At a glance
- Originator Aventis
- Class Antiasthmatics; Quinolines; Small molecules
- Mechanism of Action Cell membrane modulators; Mast cell stabilisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
- Discontinued Peptic ulcer
Most Recent Events
- 11 Aug 1997 No-Development-Reported for Allergic rhinitis (PO)
- 11 Aug 1997 No-Development-Reported for Asthma in USA (PO)
- 19 Sep 1994 Discontinued - Unspecified phase in Allergic rhinitis (PO)